XML 44 R34.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Revenue (Disaggregation of Revenue by Product) (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Disaggregation of Revenue [Line Items]    
Revenue $ 8,768.0 $ 6,960.0
U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 5,694.4 4,436.2
Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 3,073.7 2,523.9
Diabetes and obesity    
Disaggregation of Revenue [Line Items]    
Revenue 5,493.0 4,190.4
Diabetes and obesity | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 4,090.0 3,075.0
Diabetes and obesity | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 1,403.0 1,115.4
Mounjaro®    
Disaggregation of Revenue [Line Items]    
Revenue 1,806.5 568.5
Mounjaro® | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 1,520.4 536.4
Mounjaro® | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 286.2 32.0
Trulicity®    
Disaggregation of Revenue [Line Items]    
Revenue 1,456.3 1,977.1
Trulicity® | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 1,081.9 1,547.4
Trulicity® | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 374.4 429.7
Jardiance    
Disaggregation of Revenue [Line Items]    
Revenue 686.5 577.5
Jardiance | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 368.2 329.4
Jardiance | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 318.3 248.1
Humalog®    
Disaggregation of Revenue [Line Items]    
Revenue 538.7 460.9
Humalog® | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 338.3 271.6
Humalog® | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 200.4 189.3
Zepbound®    
Disaggregation of Revenue [Line Items]    
Revenue 517.4 0.0
Zepbound® | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 517.4 0.0
Zepbound® | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 0.0 0.0
Humulin®    
Disaggregation of Revenue [Line Items]    
Revenue 206.2 252.0
Humulin® | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 153.1 198.8
Humulin® | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 53.1 53.2
Basaglar®    
Disaggregation of Revenue [Line Items]    
Revenue 157.6 209.3
Basaglar® | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 83.2 135.4
Basaglar® | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 74.3 73.9
Other diabetes and obesity    
Disaggregation of Revenue [Line Items]    
Revenue 123.8 145.1
Other diabetes and obesity | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 27.5 56.0
Other diabetes and obesity | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 96.3 89.2
Oncology    
Disaggregation of Revenue [Line Items]    
Revenue 1,810.0 1,356.0
Oncology | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 998.3 753.4
Oncology | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 811.7 602.6
Verzenio®    
Disaggregation of Revenue [Line Items]    
Revenue 1,050.3 750.9
Verzenio® | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 638.2 461.1
Verzenio® | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 412.1 289.8
Cyramza®    
Disaggregation of Revenue [Line Items]    
Revenue 229.9 236.8
Cyramza® | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 107.2 100.6
Cyramza® | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 122.6 136.1
Erbitux®    
Disaggregation of Revenue [Line Items]    
Revenue 144.6 129.9
Erbitux® | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 132.1 118.8
Erbitux® | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 12.5 11.1
Tyvyt®    
Disaggregation of Revenue [Line Items]    
Revenue 116.7 61.0
Tyvyt® | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 0.0 0.0
Tyvyt® | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 116.7 61.0
Other oncology    
Disaggregation of Revenue [Line Items]    
Revenue 268.5 177.4
Other oncology | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 120.8 72.9
Other oncology | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 147.8 104.6
Immunology    
Disaggregation of Revenue [Line Items]    
Revenue 834.0 777.8
Immunology | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 397.2 354.5
Immunology | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 436.8 423.3
Taltz®    
Disaggregation of Revenue [Line Items]    
Revenue 604.1 527.0
Taltz® | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 347.1 312.2
Taltz® | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 257.0 214.8
Olumiant®    
Disaggregation of Revenue [Line Items]    
Revenue 217.4 228.9
Olumiant® | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 46.3 42.3
Olumiant® | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 171.0 186.5
Other immunology    
Disaggregation of Revenue [Line Items]    
Revenue 12.5 22.0
Other immunology | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 3.8 0.0
Other immunology | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 8.8 22.0
Neuroscience    
Disaggregation of Revenue [Line Items]    
Revenue 389.1 360.5
Neuroscience | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 163.2 144.5
Neuroscience | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 225.9 216.0
Emgality®    
Disaggregation of Revenue [Line Items]    
Revenue 225.7 154.3
Emgality® | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 125.0 108.7
Emgality® | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 100.7 45.6
Other neuroscience    
Disaggregation of Revenue [Line Items]    
Revenue 163.4 206.2
Other neuroscience | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 38.2 35.8
Other neuroscience | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 125.2 170.4
Other    
Disaggregation of Revenue [Line Items]    
Revenue 241.9 275.3
Other | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 45.7 108.7
Other | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 196.2 166.6
Cialis®    
Disaggregation of Revenue [Line Items]    
Revenue 139.3 100.3
Cialis® | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 5.9 7.6
Cialis® | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 133.4 92.7
Forteo®    
Disaggregation of Revenue [Line Items]    
Revenue 61.3 122.3
Forteo® | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 21.7 70.7
Forteo® | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 39.5 51.7
Other    
Disaggregation of Revenue [Line Items]    
Revenue 41.3 52.8
Other | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 18.1 30.5
Other | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue $ 23.3 $ 22.2